APRIL DURBIN: Open Payments
NPI 1063951101 · INDEPENDENCE, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,041 in 122 payments from 19 companies in 2025. Trend: 2023 $2,164 · 2024 $2,089 · 2025 $2,041
Food & beverage: $2,041
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 34 | $541 |
| Lilly USA, LLC | 22 | $326 |
| AstraZeneca Pharmaceuticals LP | 16 | $290 |
| Novo Nordisk Inc | 11 | $172 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $136 |
| Amgen Inc. | 5 | $87 |
| Exact Sciences Corporation | 4 | $87 |
| Sumitomo Pharma America, Inc. | 4 | $76 |
| Aimmune Therapeutics, Inc. | 4 | $72 |
| Kowa Pharmaceuticals America, Inc. | 3 | $47 |
Products named: VRAYLAR, QULIPTA, MOUNJARO, CAPLYTA, BREZTRI, UBRELVY, AIRSUPRA, KISUNLA.
Industry payments across MO — which companies pay providers there.
